Prostate Cancer Clinical Trial
SBRT for Organ Confined Prostate Cancer
Summary
Stereotactic Body Radiation Therapy (SBRT) is a method of delivering radiation which can target the tumor more precisely and cause less damage to normal tissue. This is a Phase I research study looking at the safety of the dose of SBRT in organ confined prostate cancer.
Full Description
Radiation options for treating early stage prostate cancer can include external radiation therapy, which is radiation given outside the body, or prostate seed implant, which is placing radioactive seeds directly into the prostate. For external beam radiation therapy, treatment can last up to 9 weeks. Treatment is given daily, Monday through Friday. This may not be the most convenient option for some patients.
One way to potentially overcome this challenge is to deliver a more intense dose of radiation treatment to the tumor over a shorter amount of time. Stereotactic Body Radiation Therapy (SBRT) is a technique that treats the prostate with fewer treatments and can decrease the effect of radiation to the surrounding tissues. This study is a Phase I research study, which means that it will look at the safety of the dose of the SBRT. While SBRT itself is a standard of care method to administer radiation therapy, there has not been a specific dose outlined in the past. The aim of this study is to determine the dose that will treat the prostate cancer but cause the least amount of side effects.
Eligibility Criteria
Inclusion Criteria:
Willing and capable to provide informed consent
Signed study specific informed consent
Prostate specific-antigen (PSA) ≤ 10 Gleason 2-7
Appropriate staging studies identifying as American Joint Committee on Cancer (AJCC) stage T1a, T1b, T1c, T2a, T2b
No direct evidence of regional or distant metastases after appropriate staging studies
Histologic confirmation of cancer by biopsy
Age ≥ 18
Karnofsky Performance Status must be ≥ 70
American Urological Association (AUA) score must be ≤ 15 (alpha blockers allowed)
Exclusion Criteria:
Female
Positive lymph nodes of metastatic disease from prostate cancer
Prior invasive malignancy unless disease free for a minimum of 3 years (carcinoma in situ of the breast, oral cavity, or non-melanomatous skin cancer are all permissable)
T2c, T3, or T4 tumors
Previous pelvic radiotherapy
Previous surgery or chemotherapy for prostate cancer
Previous transurethral resection of the prostate (TURP) or cryotherapy to the prostate
Concomitant hormonal therapy
Concomitant antineoplastic therapy (including surgery, cryotherapy, conventionally fractionated radiotherapy, and chemotherapy) while on this protocol
History of Crohn's Disease or Ulcerative Colitis
Previous significant obstructive symptoms; AUA score must be ≤ 15 (alpha blockers allowed)
Significant psychiatric illness
Severe, active co-morbidity defined as follows:
Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months.
Transmural myocardial infarction within the last 6 months
Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before registration
Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol
Acquired Immune Deficiency Syndrome (AIDS) based upon current Center Disease Control and Prevention (CDC) definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. Protocol-specific requirements may also exclude immuno-compromised patients.
History of treatment with potent immunosuppressive drugs for such conditions as post organ transplant, severe rheumatoid arthritis, etc. within the past 6 months.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Lake Success New York, 11042, United States
How clear is this clinincal trial information?